Publication | Closed Access
Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens.
38
Citations
20
References
1999
Year
VaccinationCancer ImmunosurveillanceImmunologyTumor Antigen Gp100ImmunodominanceVirologyTherapeutic VaccineAutoimmunityAntigen ProcessingImmunotherapeuticsVaccine DesignImmunotherapyMedicineCell BiologyMouse TransgenicTumor MicroenvironmentRecombinant Virus VaccinationAnchor-fixing Epitopes
To study the induction of anti-"self" CD8+ T-cell reactivity against the tumor antigen gp100, we used a mouse transgenic for a chimeric HLA-A*0201/H-2 Kb molecule (A2/Kb). We immunized the mice with a recombinant vaccinia virus encoding a form of gp100 that had been modified at position 210 (from a threonine to a methionine) to increase epitope binding to the restricting class I molecule. Immunogens containing the "anchor-fixed" modification elicited anti-self CD8+ T cells specific for the wild-type gp100(209-217) peptide pulsed onto target cells. More important, these cells specifically recognized the naturally presented epitope on the surface of an A2/Kb-expressing murine melanoma, B16. These data indicate that anchor-fixing epitopes could enhance the function of recombinant virus-based immunogens.
| Year | Citations | |
|---|---|---|
Page 1
Page 1